Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KQB368 in Advanced Solid Malignancies With KRAS G12S or G12C Mutations
NCT07542704Phase 1Recruiting
- Sponsor
- Kumquat Biosciences
- Start
- May 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of KQB368 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and 1 more, sponsored by Kumquat Biosciences. Primary endpoint: Safe dose of KQB368 as a monotherapy up to 44 months. Started May 2026; status: recruiting.
02
Drugs
KQB368
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)uterine cancer
Beyond the preview
Go deeper on NCT07542704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542704.